Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity
NEW YORK, Sept. 6, 2011 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0610886/Licensing-Strategies-of-Large-Pharmaceutical-Companies---Weak-RD-Pipelines-and-the-Patent-Cliff-Stimulate-In-Licensing-Activity.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity
Summary
GBI Research has released its latest research, "Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity" which provides insights into the licensing agreements of large pharmaceutical companies. The report provides an in-depth analysis of the major licensing agreement trends in the pharmaceutical industry along with product and technology licensing trends. In addition, the report also analyzes the top 20 pharmaceutical companies with respect to the licensing agreement activities.
The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts.
Scope
The scope of this report includes -
- Major market trends that are expected to shape the licensing and deal making landscape in pharmaceutical industry
- Trends in deals for product licensing and technology licensing agreements.
- Extensive research and analysis of the licensing activity of large pharmaceutical companies.
- Licensing and deal making segmentation of top 20 in the pharmaceutical companies by phase, type, geography and value
- Company profiles of leading biotech companies active in licensing and deal making
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop market-entry and market expansion strategies by identifying the leading areas for licensing and deal making in the pharmaceutical industry.
- Enable better product lifecycle management by identifying key phases of product licensing agreements.
- Develop segment specific strategies for licensing and deal making in pharmaceutical industry.
- Develop key strategic initiatives by understanding the key licensing and deal making focus areas of leading pharma companies.
- Accelerate and strengthen your market position by identifying key companies for licensing agreements.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 7
1.2 List of Figures 8
2 Licensing Strategies In Large Pharmaceutical Companies – Introduction 13
2.1 Licensing Agreement – An Authorization 13
2.2 GBI Research Report Guidance 15
3 Trends in In-licensing and Out-licensing Agreements 16
3.1 In-Licensing Compensates For Declining Internal R&D 16
3.2 Licensing Key To Combat Patent Cliff 16
3.3 Spiraling Cost of Licensing Deals 16
3.3.1 Competition to Restock Pipelines 16
3.3.2 Biotechs Push Products through Further Stages of Development 16
4 Product Licensing 18
4.1 Licensing Offsets Deficiencies in Internal Pipelines and Portfolios 18
4.2 Oncology Therapy Area Spearheads Licensing Agreements in Big Pharma Companies 18
4.3 Licensing Deals in Asia-Pacific on the Rise 19
5 Technology Licensing Deals 20
5.1 Importance of Technology In-Licensing 20
5.2 Technology Licensing With Universities 20
6 Major Licensing Deals of Big Pharma Companies – 2010 21
6.1 High Value Deals of Big Pharma Players – 2010 21
6.1.1 GlaxoSmithKline Enters Into Licensing Agreement with Isis Pharmaceuticals 21
6.1.2 Sanofi-Aventis enters Into Licensing Agreement with Avila Therapeutics 22
6.1.3 Boehringer Ingelheim Enters into Licensing Agreement With f-star Biotechnologische 22
6.1.4 Merck Amends Its Collaboration Agreement with Ariad Pharmaceuticals 23
6.1.5 AstraZeneca Enters Into Licensing Agreement with Rigel Pharmaceuticals 23
7 Licensing Strategies of Major Pharma Companies 24
7.1 GlaxoSmithKline 24
7.1.1 Overview 24
7.1.2 Licensing Agreements – GSK 24
7.1.3 By Value 25
7.1.4 By Type 27
7.1.5 By Geography 28
7.1.6 By Therapy Area 29
7.1.7 By Phase 30
7.2 J&J 31
7.2.1 Overview 31
7.2.2 Licensing Agreements – J&J 31
7.2.3 By Value 32
7.2.4 By Type 34
7.2.5 By Geography 35
7.2.6 By Therapy Area 36
7.2.7 By Phase 37
7.3 Roche 38
7.3.1 Overview 38
7.3.2 Licensing Agreements – Roche 38
7.3.3 By Value 39
7.3.4 By Type 41
7.3.5 By Geography 42
7.3.6 By Therapy Area 43
7.3.7 By Phase 44
7.4 Abbott 45
7.4.1 Overview 45
7.4.2 Licensing Agreements – Abbott 45
7.4.3 By Value 46
7.4.4 By Type 47
7.4.5 By Geography 48
7.4.6 By Therapy Area 49
7.4.7 By Phase 50
7.5 Eli Lilly 51
7.5.1 Overview 51
7.5.2 Licensing Agreements – Eli Lilly 51
7.5.3 By Value 52
7.5.4 By Type 54
7.5.5 By Geography 55
7.5.6 By Therapy Area 56
7.5.7 By Phase 57
7.6 Novartis 58
7.6.1 Overview 58
7.6.2 Licensing Agreements – Novartis 58
7.6.3 By Value 59
7.6.4 By Type 61
7.6.5 By Geography 62
7.6.6 By Therapy Area 63
7.6.7 By Phase 64
7.7 Sanofi 65
7.7.1 Overview 65
7.7.2 Licensing Agreements – Sanofi 65
7.7.3 By Value 66
7.7.4 By Type 68
7.7.5 By Geography 69
7.7.6 By Therapy Area 70
7.7.7 By Phase 71
7.8 Takeda 72
7.8.1 Overview 72
7.8.2 Licensing Agreements – Takeda 72
7.8.3 By Value 74
7.8.4 By Type 75
7.8.5 By Geography 75
7.8.6 By Therapy Area 76
7.8.7 By Phase 77
7.9 Pfizer 78
7.9.1 Overview 78
7.9.2 Licensing Agreements – Pfizer 78
7.9.3 By Value 79
7.9.4 By Type 81
7.9.5 By Geography 82
7.9.6 By Therapy Area 83
7.9.7 By Phase 84
7.10 Bristol-Myers Squibb 85
7.10.1 Overview 85
7.10.2 Licensing Agreements – Bristol-Myers Squibb 85
7.10.3 By Value 86
7.10.4 By Type 88
7.10.5 By Geography 89
7.10.6 By Therapy Area 90
7.10.7 By Phase 91
7.11 Boehringer-Ingelheim 92
7.11.1 Overview 92
7.11.2 Licensing Agreements – Boehringer Ingelheim 92
7.11.3 By Value 93
7.12 Merck & Co. 94
7.12.1 Overview 94
7.12.2 Licensing Agreements – Merck & Co. 94
7.12.3 By Value 95
7.12.4 By Type 97
7.12.5 By Geography 98
7.12.6 By Therapy Area 99
7.12.7 By Phase 100
7.13 Bayer 101
7.13.1 Overview 101
7.13.2 Licensing Agreements – Bayer 101
7.13.3 By Value 102
7.13.4 By Type 104
7.13.5 By Geography 105
7.13.6 By Therapy Area 106
7.13.7 By Phase 107
7.14 AstraZeneca 108
7.14.1 Overview 108
7.14.2 Licensing Agreements – AstraZeneca 108
7.14.3 By Value 109
7.14.4 By Type 111
7.14.5 By Geography 112
7.14.6 By Therapy Area 113
7.14.7 By Phase 114
7.15 Astellas 115
7.15.1 Overview 115
7.15.2 Licensing Agreements – Astellas 115
7.15.3 By Value 116
7.15.4 By Type 118
7.15.5 By Geography 119
7.15.6 By Therapy Area 120
7.15.7 By Phase 121
7.16 Daiichi-Sankyo 122
7.16.1 Overview 122
7.16.2 Licensing Agreements – Daiichi Sankyo 122
7.16.3 By Value 123
7.16.4 By Type 124
7.16.5 By Geography 125
7.16.6 By Therapy Area 126
7.16.7 By Phase 127
7.17 Teva Pharma 128
7.17.1 Overview 128
7.17.2 Licensing Agreements – Teva 128
7.17.3 By Value 129
7.17.4 By Geography 132
7.17.5 By Therapy Area 132
7.17.6 By Phase 133
7.18 Eisai 134
7.18.1 Overview 134
7.18.2 Licensing Agreements – Eisai 134
7.18.3 By Value 135
7.18.4 By Type 136
7.18.5 By Geography 137
7.18.6 By Therapy Area 138
7.18.7 By Phase 139
7.19 Baxter 140
7.19.1 Overview 140
7.19.2 Licensing Agreements – Baxter 140
7.19.3 By Value 141
7.19.4 By Type 142
7.19.5 By Therapy Area 143
7.20 Amgen 144
7.20.1 Overview 144
7.20.2 Licensing Agreements – Amgen 144
7.20.3 By Value 145
7.20.4 By Geography 146
7.20.5 By Therapy Area 147
7.20.6 By Phase 148
8 Licensing Strategies In Large Pharmaceutical Companies – Appendix 149
8.1 Market Definitions 149
8.2 Abbreviations 149
8.3 Research Methodology 149
8.3.1 Coverage 150
8.3.2 Secondary Research 150
8.3.3 Primary Research 150
8.3.4 Expert Panel Validation 151
8.4 Section Wise Methodology 151
8.4.1 Trends in In-licensing and Out-licensing Agreements 151
8.4.2 Product Licensing 151
8.4.3 Technology Licensing Deals 151
8.4.4 Major Licensing Deals of Big Pharma Companies – 2010 152
8.4.5 Licensing Strategies of Major Pharmaceutical Companies 152
8.5 Contact Us 152
8.6 Disclaimer 152
8.7 Sources 153
1.1 List of Tables
Table 1: Licensing Strategies in Large Pharmaceutical Companies, Global, Licensing Deals By Value 2004–2010 17
Table 2: Licensing Strategies in Large Pharmaceutical Companies, GSK, Licensing Deals By Value, 2006–2010 25
Table 3: Licensing Strategies in Large Pharmaceutical Companies, J&J, Licensing Deals By Value, 2006 – 2010 32
Table 4: Licensing Strategies in Large Pharmaceutical Companies, Roche, Licensing Deals By Value, 2006–2010 39
Table 5: Licensing Strategies in Large Pharmaceutical Companies, Eli Lilly, Licensing Deals By Value, 2006–2010 52
Table 6: Licensing Strategies in Large Pharmaceutical Companies, Novartis, Licensing Deals By Value, 2006–2010 59
Table 7: Licensing Strategies in Large Pharmaceutical Companies, Sanofi, Licensing Deals By Value, 2006 – 2010 66
Table 8: Licensing Strategies in Large Pharmaceutical Companies, Takeda, Licensing Deals By Value, 2006 – 2010 73
Table 9: Licensing Strategies in Large Pharmaceutical Companies, Pfizer, Licensing Deals By Value, 2006 – 2010 79
Table 10: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Licensing Deals By Value, 2006 – 2010 86
Table 11: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Licensing Deals By Value, 2006–2010 95
Table 12: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Value, 2006 – 2010 102
Table 13: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Licensing Deals By Value, 2006 – 2010 109
Table 14: Licensing Strategies in Large Pharmaceutical Companies, Astellas, Licensing Deals By Value, 2006 – 2010 116
Table 15: Licensing Strategies in Large Pharmaceutical Companies, Teva, Licensing Deals By Value, 2006 – 2010 129
1.2 List of Figures
Figure 1: Licensing Strategies in Large Pharmaceutical Companies , Pharmaceutical Licensing Life Cycle, 2010 13
Figure 2: Licensing Strategies in Large Pharmaceutical Companies, Top 20 Pharmaceuticals Licensing Deals, 2005–2010 14
Figure 3: Licensing Strategies in Large Pharmaceutical Companies, Global, Licensing Deals By Value, 2004–2010 17
Figure 4: Licensing Strategies in Large Pharmaceutical Companies, Global, Licensing Deals By Therapy Area, 2010 18
Figure 5: Licensing Strategies in Large Pharmaceutical Companies, Top 20 Pharmaceutical Companies, Number of Licensing Deals, 2010 21
Figure 6: Licensing Strategies in Large Pharmaceutical Companies, GSK, Number of Licensing Deals, 2005 – Q1 2011 24
Figure 7: Licensing Strategies in Large Pharmaceutical Companies, GSK, Licensing Deals By Value, 2006–2010 25
Figure 8: Licensing Strategies in Large Pharmaceutical Companies, GSK, Number of Licensing Deals By Value, 2005 – Q1 2011 26
Figure 9: Licensing Strategies in Large Pharmaceutical Companies, GSK, Licensing Deals By Type, 2009 – Q1 2011 27
Figure 10: Licensing Strategies in Large Pharmaceutical Companies, GSK, Licensing Deals By Geography, 2009 – Q1 2011 28
Figure 11: Licensing Strategies in Large Pharmaceutical Companies, GSK, Licensing Deals By Therapy Area, 2009–Q1 2011 29
Figure 12: Licensing Strategies in Large Pharmaceutical Companies, GSK, Licensing Deals By Phase, 2009 – Q1 2011 30
Figure 13: Licensing Strategies in Large Pharmaceutical Companies, J&J, Number of Licensing Deals, 2005–Q1 2011 31
Figure 14: Licensing Strategies in Large Pharmaceutical Companies, J&J, Licensing Deals By Value, 2006–2010 32
Figure 15: Licensing Strategies in Large Pharmaceutical Companies, J&J, Licensing Deals By Value, 2005 – Q1 2011 33
Figure 16: Licensing Strategies in Large Pharmaceutical Companies, J&J, Licensing Deals By Type, 2009 – Q1 2011 34
Figure 17: Licensing Strategies in Large Pharmaceutical Companies, J&J, Licensing Deals By Geography 2009 – Q1 2011 35
Figure 18: Licensing Strategies in Large Pharmaceutical Companies, J&J, Licensing Deals By Therapy Area, 2009 – Q1 2011 36
Figure 19: Licensing Strategies in Large Pharmaceutical Companies, J&J, Licensing Deals By Phase, 2009 – Q1 2011 37
Figure 20: Licensing Strategies in Large Pharmaceutical Companies, Roche, Number of Licensing Deals, 2005 – Q1 2011 38
Figure 21: Licensing Strategies in Large Pharmaceutical Companies, Roche, Licensing Deals By Value, 2006–2010 39
Figure 22: Licensing Strategies in Large Pharmaceutical Companies, Roche, Licensing Deals By Value, 2005 – Q1 2011 40
Figure 23: Licensing Strategies in Large Pharmaceutical Companies, Roche, Licensing Deals By Type, 2009–Q1 2011 41
Figure 24: Licensing Strategies in Large Pharmaceutical Companies, Roche, Licensing Deals By Geography, 2009 – Q1 2011 42
Figure 25: Licensing Strategies in Large Pharmaceutical Companies, Roche, Licensing Deals By Therapy Area, 2009 – Q1 2011 43
Figure 26: Licensing Strategies in Large Pharmaceutical Companies, Roche, Licensing Deals By Phase, 2009 – Q1 2011 44
Figure 27: Licensing Strategies in Large Pharmaceutical Companies, Abbott, Number of Licensing Deals, 2005 – 2010 45
Figure 28: Licensing Strategies in Large Pharmaceutical Companies, Abbott, Number of Licensing Deals, By Value, 2005–2010 46
Figure 29: Licensing Strategies in Large Pharmaceutical Companies, Abbott, Licensing Deals By Type, 2009 – Q1 2011 47
Figure 30: Licensing Strategies in Large Pharmaceutical Companies, Abbott, Licensing Deals By Geography 2009 – Q1 2011 48
Figure 31: Licensing Strategies in Large Pharmaceutical Companies, Abbott, Licensing Deals By Therapy Area, 2009 – Q1 2011 49
Figure 32: Licensing Strategies in Large Pharmaceutical Companies, Abbott, Licensing Deals By Phase, 2009 – Q1 2011 50
Figure 33: Licensing Strategies in Large Pharmaceutical Companies, Eli Lilly, Number of Licensing Deals, 2005 – Q1 2011 51
Figure 34: Licensing Strategies in Large Pharmaceutical Companies, Eli Lilly, Licensing Deals By Value, 2006–2010 52
Figure 35: Licensing Strategies in Large Pharmaceutical Companies, Eli Lilly, Number of Licensing Deals, By Value, 2005 – Q1 2011 53
Figure 36: Licensing Strategies in Large Pharmaceutical Companies, Eli Lilly, Licensing Deals By Type, 2009 – Q1 2011 54
Figure 37: Licensing Strategies in Large Pharmaceutical Companies, Eli Lilly, Licensing Deals By Geography, 2009 – Q1 2011 55
Figure 38: Licensing Strategies in Large Pharmaceutical Companies, Eli Lilly, Licensing Deals By Therapy Area, 2009 – Q1 2011 56
Figure 39: Licensing Strategies in Large Pharmaceutical Companies, Eli Lilly, Licensing Deals By Phase, 2009 – Q1 2011 57
Figure 40: Licensing Strategies in Large Pharmaceutical Companies, Novartis, Number of Licensing Deals, 2005 – Q1 2011 58
Figure 41: Licensing Strategies in Large Pharmaceutical Companies, Novartis, Licensing Deals By Value, 2006–2010 59
Figure 42: Licensing Strategies in Large Pharmaceutical Companies, Novartis, Number of Licensing Deals By Value, 2005 – Q1 2011 60
Figure 43: Licensing Strategies in Large Pharmaceutical Companies, Novartis, Licensing Deals By Type, 2009 – Q1 2011 61
Figure 44: Licensing Strategies in Large Pharmaceutical Companies, Novartis, Licensing Deals By Geography, 2009 – Q1 2011 62
Figure 45: Licensing Strategies in Large Pharmaceutical Companies, Novartis, Licensing Deals By Therapy Area, 2009 – Q1 2011 63
Figure 46: Licensing Strategies in Large Pharmaceutical Companies, Novartis, Licensing Deals By Phase, 2009 – Q1 2011 64
Figure 47: Licensing Strategies in Large Pharmaceutical Companies, Sanofi, Number of Licensing Deals, 2005 – Q1 2011 65
Figure 48: Licensing Strategies in Large Pharmaceutical Companies, Sanofi, Licensing Deals By Value, 2006 – 2010 66
Figure 49: Licensing Strategies in Large Pharmaceutical Companies, Sanofi, Number of Licensing Deals, By Value, 2005 – Q1 2011 67
Figure 50: Licensing Strategies in Large Pharmaceutical Companies, Sanofi, Licensing Deals By Type, 2009 – Q1 2011 68
Figure 51: Licensing Strategies in Large Pharmaceutical Companies, Sanofi, Licensing Deals By Geography, 2009 – Q1 2011 69
Figure 52: Licensing Strategies in Large Pharmaceutical Companies, Sanofi, Licensing Deals By Therapy Area, 2009 – Q1 2011 70
Figure 53: Licensing Strategies in Large Pharmaceutical Companies, Sanofi, Licensing Deals By Phase, 2009 – Q1 2011 71
Figure 54: Licensing Strategies in Large Pharmaceutical Companies, Takeda, Number of Licensing Deals, 2005 – Q1 2011 72
Figure 55: Licensing Strategies in Large Pharmaceutical Companies, Takeda, Licensing Deals By Value, 2006 – 2010 73
Figure 56: Licensing Strategies in Large Pharmaceutical Companies, Takedak Number of Licensing Deals, By Value, 2005 – Q1 2011 74
Figure 57: Licensing Strategies in Large Pharmaceutical Companies, Takeda, Licensing Deals By Type, 2009 – Q1 2011 75
Figure 58: Licensing Strategies in Large Pharmaceutical Companies, Takeda, Licensing Deals By Geography, 2009 – Q1 2011 75
Figure 59: Licensing Strategies in Large Pharmaceutical Companies, Takeda, Licensing Deals By Therapy Area, 2009 – Q1 2011 76
Figure 60: Licensing Strategies in Large Pharmaceutical Companies, Takeda, Licensing Deals By Phase, 2009 – Q1 2011 77
Figure 61: Licensing Strategies in Large Pharmaceutical Companies, Pfizer, Number of Licensing Deals, 2005 – Q1 2011 78
Figure 62: Licensing Strategies in Large Pharmaceutical Companies, Pfizer, Licensing Deals By Value, 2006–2010 79
Figure 63: Licensing Strategies in Large Pharmaceutical Companies, Pfizer, Licensing Deals By Value, 2005 – Q1 2011 80
Figure 64: Licensing Strategies in Large Pharmaceutical Companies, Pfizer, Licensing Deals By Type, 2009 – Q1 2011 81
Figure 65: Licensing Strategies in Large Pharmaceutical Companies, Pfizer, Licensing Deals By Geography, 2009 – Q1 2011 82
Figure 66: Licensing Strategies in Large Pharmaceutical Companies, Pfizer, Licensing Deals By Therapy Area, 2009 – Q1 2011 83
Figure 67: Licensing Strategies in Large Pharmaceutical Companies, Pfizer, Licensing Deals By Phase, 2009 – Q1 2011 84
Figure 68: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Number of Licensing Deals, 2005 – Q1 2011 85
Figure 69: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Licensing Deals By Value, 2006–2010 86
Figure 70: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Licensing Deals By Value, 2005 – Q1 2011 87
Figure 71: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Licensing Deals By Type, 2009 – Q1 2011 88
Figure 72: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Licensing Deals By Geography, 2009 – Q1 2011 89
Figure 73: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Licensing Deals By Therapy Area, 2009 – Q1 2011 90
Figure 74: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Licensing Deals By Phase, 2009 – Q1 2011 91
Figure 75: Licensing Strategies in Large Pharmaceutical Companies, Boehringer Ingelheim, Number of Licensing Deals, 2005 – Q1 2011 92
Figure 76: Licensing Strategies in Large Pharmaceutical Companies, Boehringer Ingelheim, Licensing Deals By Value, 2005 – 2010 93
Figure 77: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Number of Licensing Deals, 2005 – Q1 2011 94
Figure 78: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Licensing Deals, By Value, 2006–2010 95
Figure 79: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Number of Licensing Deals, By Value, 2005 – Q1 2011 96
Figure 80: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Licensing Deals By Type, 2009 – Q1 2011 97
Figure 81: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Licensing Deals By Geography, 2009 – Q1 2011 98
Figure 82: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Licensing Deals By Therapy Area, 2009 – Q1 2011 99
Figure 83: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Licensing Deals By Phase, 2009 – Q1 2011 100
Figure 84: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Number of Licensing Deals, 2005 – Q1 2011 101
Figure 85: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Value, 2006 – 2010 102
Figure 86: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Value, 2005 – Q1 2011 103
Figure 87: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Type, 2009 – Q1 2011 104
Figure 88: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Geography, 2009 – Q1 2011 105
Figure 89: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Therapy Area, 2009 – Q1 2011 106
Figure 90: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Phase, 2009 – Q1 2011 107
Figure 91: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Number of Licensing Deals, 2005 – Q1 2011 108
Figure 92: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Licensing Deals By Value, 2006–2010 109
Figure 93: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Number of Licensing Deals By Value, 2005 – 2010 110
Figure 94: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Licensing Deals By Type, 2009 – Q1 2011 111
Figure 95: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Licensing Deals By Geography, 2009 – Q1 2011 112
Figure 96: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Licensing Deals By Therapy Area, 2009 – Q1 2011 113
Figure 97: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Licensing Deals By Phase 2009 – Q1 2011 114
Figure 98: Licensing Strategies in Large Pharmaceutical Companies, Astellas, Number of Licensing Deals, 2005 – Q1 2011 115
Figure 99: Licensing Strategies in Large Pharmaceutical Companies, Astellas, Licensing Deals By Value, 2006 – 2010 116
Figure 100: Licensing Strategies in Large Pharmaceutical Companies, Astellas, Number of Licensing Deals By Value, 2005 – Q1 2011 117
Figure 101: Licensing Strategies in Large Pharmaceutical Companies, Astellas, Licensing Deals By Type, 2009 – Q1 2011 118
Figure 102: Licensing Strategies in Large Pharmaceutical Companies, Astellas, Licensing Deals By Geography, 2009 – Q1 2011 119
Figure 103: Licensing Strategies in Large Pharmaceutical Companies, Astellas, Licensing Deals By Therapy Area, 2009 – Q1 2011 120
Figure 104: Licensing Strategies in Large Pharmaceutical Companies, Astellas, Licensing Deals By Phase, 2009 – Q1 2011 121
Figure 105: Licensing Strategies in Large Pharmaceutical Companies, Daiichi Sankyo, Number of Licensing Deals, 2005 – Q1 2011 122
Figure 106: Licensing Strategies in Large Pharmaceutical Companies, Daiichi Sankyo, Number of Licensing Deals By Value, 2005 – Q1 2011 123
Figure 107: Licensing Strategies in Large Pharmaceutical Companies, Daiichi Sankyo, Licensing Deals By Type, 2009 – Q1 2011 124
Figure 108: Licensing Strategies in Large Pharmaceutical Companies, Daiichi Sankyo, Licensing Deals By Geography, 2009 – Q1 2011 125
Figure 109: Licensing Strategies in Large Pharmaceutical Companies, Daiichi Sankyo, Licensing Deals by Therapy Area, 2009 – Q1 2011 126
Figure 110: Licensing Strategies in Large Pharmaceutical Companies, Daiichi Sankyo, Licensing Deals By Phase, 2009 – Q1 2011 127
Figure 111: Licensing Strategies in Large Pharmaceutical Companies, Teva, Number of Licensing Deals, 2005 – Q1 2011 128
Figure 112: Licensing Strategies in Large Pharmaceutical Companies, Teva, Licensing Deals By Value, 2006 – 2010 129
Figure 113: Licensing Strategies in Large Pharmaceutical Companies, Teva, Licensing Deals By Value, 2005 – Q1 2011 130
Figure 114: Licensing Strategies in Large Pharmaceutical Companies, Teva, Licensing Deals By Type, 2009 – Q1 2011 131
Figure 115: Licensing Strategies in Large Pharmaceutical Companies, Teva, Licensing Deals By Geography, 2009 – Q1 2011 132
Figure 116: Licensing Strategies in Large Pharmaceutical Companies, Teva, Licensing Deals By Therapy Area, 2009 – Q1 2011 132
Figure 117: Licensing Strategies in Large Pharmaceutical Companies, Teva, Licensing Deals By Phase, 2009 – Q1 2011 133
Figure 118: Licensing Strategies in Large Pharmaceutical Companies, Eisai, Number of Licensing Deals, 2005 – Q1 2011 134
Figure 119: Licensing Strategies in Large Pharmaceutical Companies, Eisai, Number of Licensing Deals By Value, 2005 – Q1 2011 135
Figure 120: Licensing Strategies in Large Pharmaceutical Companies, Eisai, Licensing Deals By Type, 2009 – Q1 2011 136
Figure 121: Licensing Strategies in Large Pharmaceutical Companies, Eisai, Licensing Deals By Geography, 2009 – Q1 2011 137
Figure 122: Licensing Strategies in Large Pharmaceutical Companies, Eisai, Licensing Deals By Therapy Area, 2009 – Q1 2011 138
Figure 123: Licensing Strategies in Large Pharmaceutical Companies, Eisai, Licensing Deals By Phase, 2009 – Q1 2011 139
Figure 124: Licensing Strategies in Large Pharmaceutical Companies, Baxter, Number of Licensing Deals, 2005 – Q1 2011 140
Figure 125: Licensing Strategies in Large Pharmaceutical Companies, Baxter, Number of Licensing Deals By Value, 2005 – Q1 2011 141
Figure 126: Licensing Strategies in Large Pharmaceutical Companies, Baxter, Licensing Deals By Type, 2009 – Q1 2011 142
Figure 127: Licensing Strategies in Large Pharmaceutical Companies, Baxter, Licensing Deals By Therapy Area, 2009 – Q1 2011 143
Figure 128: Licensing Strategies in Large Pharmaceutical Companies, Amgen, Number of Licensing Deals, 2005 – Q1 2011 144
Figure 129: Licensing Strategies in Large Pharmaceutical Companies, Amgen, Number of Licensing Deals By Value, 2005 – Q1 2011 145
Figure 130: Licensing Strategies in Large Pharmaceutical Companies, Amgen, Licensing Deals By Type, 2009 – Q1 2011 145
Figure 131: Licensing Strategies in Large Pharmaceutical Companies, Amgen, Licensing Deals By Geography, 2009 – Q1 2011 146
Figure 132: Licensing Strategies in Large Pharmaceutical Companies, Amgen, Licensing Deals By Therapy Area, 2009 – Q1 2011 147
Figure 133: Licensing Strategies in Large Pharmaceutical Companies, Amgen, Licensing Deals By Phase, 2009 – Q1 2011 148
Companies Mentioned
GlaxoSmithKline
J&J
Roche
Abbott
Eli Lilly
Novartis
Sanofi
Takeda
Pfizer
Bristol-Myers Squibb
Boehringer-Ingelheim
Merck & Co.
Bayer
AstraZeneca
Astellas
Daiichi-Sankyo
Teva Pharma
Eisai
Baxter
Amgen
To order this report:
Therapy Industry: Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity
Therapy Business News
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article